89bio, Inc.
Overview
89bio, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to address liver and cardio-metabolic diseases. The company aims to improve the lives of patients with serious and life-threatening conditions by advancing its product candidates through clinical development.
Therapeutic areas
Liver DiseasesCardio-Metabolic Diseases
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to 89bio, Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Related companies
NGM Biopharmaceuticals, Inc.
United States
Akero Therapeutics, Inc.
United States
Durect Corporation
USA
Gastro Innovations Incorporated
USA
Gastroenterology Research Foundation
United States
Gilead Sciences, Inc.
United States
Intercept Pharmaceuticals, Inc.
United States
Madrigal Pharmaceuticals, Inc.
United States
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.